← Leaderboards
Seungmin Hwang
University Of Chicago
$5,327,414
Attributed
$5,327,414
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2017–23$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$5,327,414 · 3
By mechanism
U19$4,418,311 · 1
DP2$510,055 · 1
R01$399,048 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Chicago
Same institution · by research overlap
- Yang-Xin Fu$17,180,976
- Thomas F Gajewski$23,743,716
- Chuan He$53,119,947
- Hans Schreiber$12,391,832
- Yimin Zou$16,553,198
Others in their field
Other Emerging Leaders on “Proteins”
- John Damon Chodera · Sloan-Kettering Inst Can Research$50,971,767
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Susan M Landau · University Of California Berkeley$47,252,026
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$40,723,314
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
Research focus
ProteinsNew Therapeutic TargetInterferonsAutophagocytosisPathogenImmuneMediatingParasitesVirusGenesNorovirusMolecularAreaBacteriaCellular BiologyIn VivoImmunityInterferon Type IiToxoplasma GondiiAlbers-Schonberg DiseaseEpidemicAnti-Infective AgentsCrispr ScreenCytokine
Grant awards (6)
RP3: Targeting ATG gene-dependent immunity for novel anti-infective therapeutics$939,459
U19 · FY2023 · AI · contact PI
RP3: Targeting ATG gene-dependent immunity for novel anti-infective therapeutics$882,760
U19 · FY2022 · AI · contact PI
RP3: Targeting ATG gene-dependent immunity for novel anti-infective therapeutics$1,177,671
U19 · FY2021 · AI · contact PI
RP3: Targeting ATG gene-dependent immunity for novel anti-infective therapeutics$1,418,421
U19 · FY2020 · AI · contact PI
Targeting by autophagy proteins for anti-tumor immunity$510,055
DP2 · FY2017 · CA · contact PI
Novel antiviral activity of interferon-gamma against viral replication complex$399,048
R01 · FY2017 · AI · contact PI